Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger K Cady

Showing results (31-40 of 68) with videos related to

Pageof 7
Sort By:
Headache|June 3, 2011
A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesic™ M) in the treatment of migraineRoger K Cady, Jerome Goldstein, Robert Nett, et al.
The Journal of Headache and Pain|February 9, 2017
Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraineRoger K Cady, Sagar Munjal, Ryan J Cady, et al.
Headache|October 1, 2009
Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptanRoger K Cady, Carrie V Vause, Tony W Ho, et al.
Headache|February 19, 2009
Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trialRoger K Cady, Ninan Mathew, Hans-Christoph Diener, et al.
Headache|May 16, 2007
Efficacy of eletriptan in migraine-related functional impairment: functional and work productivity outcomesStephen D Silberstein, Roger K Cady, Fred D Sheftell, et al.
Headache|November 13, 2010
A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraineRoger K Cady, Curtis P Schreiber, John A H Porter, et al.
Headache|May 20, 2008
Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trialSteven L Linder, Ninan T Mathew, Roger K Cady, et al.
The Journal of Headache and Pain|March 3, 2017
A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraineSagar Munjal, Elimor Brand-Schieber, Kent Allenby, et al.
Headache|November 28, 2002
Costs and outcomes of early versus delayed migraine treatment with sumatriptanMichael T Halpern, Richard B Lipton, Roger K Cady, et al.
BMC Neurology|March 20, 2021
Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trialDavid Kudrow, Roger K Cady, Brent Allan, et al.
Pageof 7

Showing results (31-40 of 68) with videos related to

Sort By:
Pageof 7
Headache|June 3, 2011
A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesic™ M) in the treatment of migraineRoger K Cady, Jerome Goldstein, Robert Nett, et al.
The Journal of Headache and Pain|February 9, 2017
Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraineRoger K Cady, Sagar Munjal, Ryan J Cady, et al.
Headache|October 1, 2009
Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptanRoger K Cady, Carrie V Vause, Tony W Ho, et al.
Headache|February 19, 2009
Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trialRoger K Cady, Ninan Mathew, Hans-Christoph Diener, et al.
Headache|May 16, 2007
Efficacy of eletriptan in migraine-related functional impairment: functional and work productivity outcomesStephen D Silberstein, Roger K Cady, Fred D Sheftell, et al.
Headache|November 13, 2010
A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraineRoger K Cady, Curtis P Schreiber, John A H Porter, et al.
Headache|May 20, 2008
Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trialSteven L Linder, Ninan T Mathew, Roger K Cady, et al.
The Journal of Headache and Pain|March 3, 2017
A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraineSagar Munjal, Elimor Brand-Schieber, Kent Allenby, et al.
Headache|November 28, 2002
Costs and outcomes of early versus delayed migraine treatment with sumatriptanMichael T Halpern, Richard B Lipton, Roger K Cady, et al.
BMC Neurology|March 20, 2021
Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trialDavid Kudrow, Roger K Cady, Brent Allan, et al.
Pageof 7